



PROSTALUND AB

Interim report January-June 2024

ProstaLund is on a good track to establish CoreTherm[®] internationally again

"With a new organisation in place, we are moving full speed ahead!"

Lund 19 August, 2024
Anders Kristensson, CEO

Second quarter

April 1 - June 30

- Net sales reached SEK 2,8 (5,3) million
- Operating profit/loss totaled SEK -7,2 million (-4,0) million
- Loss after taxes SEK -7,2 (-4,1) million
- Earnings per share, SEK (basic and diluted) amounted to SEK -0,09 (-0,07)
- Cash flow from operating activities amounted to SEK -6,6 (-0,5) million

January 1 - June 30

- Net sales reached SEK 6,3 (10,9) million
- Operating profit/loss totaled SEK -11,9 million (-7,2) million
- Loss after taxes SEK -12,0 (-7,3) million
- Earnings per share, SEK (basic and diluted) amounted to SEK -0,16 (-0,12)
- Cash flow from operating activities amounted to SEK -12,7 (-6,0) million
- Cash and cash equivalents amounted to SEK 3,4 (34,1) million as per June 30, 2024

Key figures

(SEK MILLION)	APRIL-JUNE 2024	APRIL-JUNE 2023	JAN-JUNE 2024	JAN-JUNE 2023
Net sales	2,8	5,3	6,3	10,9
Gross Margin, (%)	74,1	67,5	71,7	67,9
Operating profit/loss, EBIT	-7,2	-4,0	-11,9	-7,2
Cash flow from operating activities	-6,1	-0,5	-12,7	-6,0
Cash and cash equivalents	3,4	34,1	3,4	34,1
Average number of employees	8	9	6	9

Significant events during the period


- Two new studies with ProstaLund's Schelin Catheter® presented at the EAU in Paris on April 8
- Positive results from unannounced inspection by TÜV SÜD, regarding our regulatory authorisations conducted on April 9-10
- ProstaLund and Capio Specialistcenter AB signed on April 22 a new agreement regarding disposable materials used in CoreTherm® treatments. The agreement is over 12 months, with an option to extend. The order value is approximately SEK 1,3 million over the contract period. The agreement replaces the previous agreement with Capio Specialistcenter AB
- ProstaLund decided on May 20 that the Board of Directors intends to decide on a rights issue of units for an initial issue amount of around 29 MSEK
- The preliminary investigation towards the former Chairman and major shareholders of the Company was closed on May 23
- ProstaLund received a certificate with MDR and ISO13485 from TÜV SÜD on May 27
- The communique from the annual general meeting was published on May 30
- New agreement signed on May 31st regarding CoreTherm® treatments in Austria
- Bridge loan amounting to 4 MSEK was signed with the main owner on June 10
- New agreement signed on June 24 regarding CoreTherm® treatments in Arhus, Denmark
- The outcome of the rights issue was published on June 28. Around 80 percent or SEK 23 million was reached before deduction of the costs related to the transaction

Significant events after the end of the period


- ProstaLund informed on July 3rd that a direct issue of units instead of cash compensation to one Guarantor will be performed in connection with the rights issue
- ProstaLund informed on July 11 that it will announce the last day of trading in BTUs after the rights issue has been registered.
- ProstaLund informed on July 17 the last day of trading in BTUs and the first day of trading in warrants of series TO 3.

Overview of the company's development

Number of CoreTherm® treatments sold in the Nordic region 2020-2024




Sales development per quarter, 2020-2024 (SEKt)



Quarterly financial performance

(KSEK)	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Net sales	2 816	3 500	6 418	4 791	5 335	5 518
Gross profit/loss	2 087	2 440	4 718	3 507	3 602	3 763
Gross margin (%)	74%	70%	74%	73%	68%	68%
Overhead costs	-9 242	-7 180	-8 454	-9 570	-7 260	-6 906
Operating profit/loss	-7 162	-4 732	-3 461	-6 231	-4 022	-3 143
Profit/loss for the period	-7 209	-4 759	-3 489	-6 270	-4 074	-3 183
Cash flow	-3 564	-8 075	-7 527	-11 516	28 130	-5 930

Sales distributed by category (SEKt)



CEO update

The first half of 2024 has been eventful for ProstaLund, and it is gratifying that the new management team has now been fully in place since June and that we can now work at full speed ahead during the autumn.

In terms of sales, we have seen a lower sales volume compared to previous quarters, and the result for CoreTherm® has been negatively impacted by a generally lower number of treatments performed at both private clinics and hospitals, as a result of reduced patient inflow in both Sweden and Denmark. We are now reviewing our marketing activities to ensure patient inflow to the Nordic clinics through both targeted campaigns and advertising.

During the past quarter, the new sales and marketing organisation has had a strong focus on meeting both existing and new customers for both CoreTherm® and stand-alone products. In summary, we have received a positive image and appreciation of our products and there is capacity to increase the number of CoreTherm® treatments, so the focus is on strengthening our marketing activities directly to patients.

I april månad deltog vi på den europeiska urologkongressen EAU i Paris, med både utställning, presentation och kundarrangemang där vi hade stort internationellt intresse för företagets produkter. I Paris presenterades även två italienska studier med gott resultat för Schelinkatetern, vidare i maj deltog vi på en BPH konferens i Bordeaux där Sonny Schelin föreläste om Schelin katetern samt CoreTherm® Concept, vilket skapade stort intresse ifrån de franska urologerna. Under kvartalet har vi även tecknat avtal med två nya CoreTherm® kunder, en i Danmark och en i Österrike.

We are now working with full focus on:

1. Driving treatment development for CoreTherm® in the Nordics
2. Finalise and launch our new platform CoreTherm® Eagle during the year
3. Resuming the 510-K application for the US market and the discussion with the FDA

In conclusion, we see good prospects for a return to previous normal sales levels and that we can start adding new customers with the launch of CoreTherm® Eagle, both in the Nordic region and internationally.

We look forward to an exciting autumn and thank our shareholders for your support and commitment on our journey forward!



Lund 19 August, 2024
Anders Kristensson
CEO

Financial information

Net sales and profit/loss

Net sales amounted to SEK 2,816 (5,335) thousand during the second quarter, which was a 47,2 percent decrease compared to the same period last year. All markets and product categories show a weaker development during the period, due to lower patient flows for CoreTherm® treatments and the co-operation with distributors for the stand-alone products has not started as planned.

The gross margin was strengthened during the quarter and amounted to 74,1% (67,5).

The operating loss for the second quarter amounted to SEK -7,162 (-4,074) thousand.

Loss after tax amounted to SEK -7,209 (-4,074) thousand.

Net sales for the period January to June amounted to SEK 6,316 (10,853) thousand, a decline with 41,8 percent.

The gross margin for the first six months amounted to 71,7% (67,9).

The operating loss for the period January to June amounted to SEK -11,894 (7,165) thousand.

Loss after tax for the same period amounted to SEK -11,968 (7,257) thousand.

Investments

Investments in property, plant & equipment amounted to SEK 51 (101) thousand for the second quarter. Investments in intangible assets amounted to SEK 1,354 (712) thousand, which mainly relates to the company's new platform, CoreTherm® Eagle.

For the first six months of 2024 Investments in property, plant & equipment amounted to SEK 51 (101) thousand. Investments in intangible assets amounted to SEK 2,718 (1,027) thousand.

Financial position and financing

Cash flow from current operations for the second quarter amounted to SEK -6,089 (-491) thousand.

For the first half of the year the cash flow from current operations amounted to SEK -12,700 (-6,006) thousand.

The company received in June 2024 a bridge loan of SEK 4 million from the main owner Mats Alyhr. The interest rate has been set at market terms.

This short-term financing including interest was fully repaid on July 15.

A right issue was performed during June which was signed up to 80% of the asked amount and contributed SEK 23 million in new capital before transaction costs. The issue proceeds were received on July 12.

Equity amounted to SEK 43,321 (64,269) thousand, and the equity ratio amounted to 78 (82) percent.

Cash and cash equivalents at the end of the period amounted to SEK 3,380 (34,062) thousand.

Organisation

The number of people employed was nine (ten) at the end of the period. The employees included six (six) women and three (four) men. The average number of employees was eight. The number of consultants was seven. The process of merging Nordisk Medicin & Teknik AB with ProstaLund AB has begun, in order to simplify the structure and reduce costs. The merge is expected to be finalized during the third quarter 2024.

Research and development

Development activities are conducted in-house in collaboration with technical consultants and external clinics. Development activities are focused on new development

and further refinement of the current product portfolio.

Insurance

ProstaLund has common corporate insurance, which also includes product liability. The insurance is subject to ongoing review. The Board of Directors has determined that the corporate insurance is adapted to the current scope of operations.

Disputes

ProstaLund is not a party in any legal disputes or arbitrations. The Board of Directors is not aware of any circumstances that could lead to any such legal processes being imminent.

Risk factors

ProstaLund is affected by a number of risks whose effects could have a negative impact on its future, earnings or financial position.

The latest annual report and prospectus, which is available at the company's website, www.prostalund.se, contains a description of the risk factors. The risk factors that are judged to be of the greatest importance are listed below, in no particular order:

- Dependence on financing
- Dependence on key personnel
- Regulatory approvals
- Product liability
- Currency risk
- Competition
- Disputes
- Changes in legislation

Prerequisites for continued operation

This financial information has been prepared based on the assumption of continued operations. The company has historically reported losses. In preparing the report, management has based its assumptions on existing cash and cash equivalents, increased sales and the possibility of other financing.

There are uncertainties that could lead to significant doubts to continuing operations if the assumptions above are not fulfilled.

The management and the Board of Directors are aware that there are uncertainties in the estimation of future cash flows as well as uncertainties in the financing of operations. The current assessment is that the conditions for positive development over time are good and that new financing of the company would be possible if needed. If the Group for some reason can't continue to operate, it may affect the Group's ability to realize the carrying amount of the assets, especially related to capitalized expenses for development work, and to pay debts at a normal rate and in the amounts included in the Group's interim report.

Transactions with related parties

Contracts with members of the Board of Directors

The Company has entered into consultancy agreements with some of its Directors. The consultancy agreements regulate the Board members' performance of assignments that cannot be regarded as tasks normally incumbent on a Board member. The fee for work under the consultancy agreement amounts to SEK 1 800 per hour. Other members of the Board and the CEO must approve such work before it is carried out.

Royalty agreement

The company has previously entered into a royalty agreement with Schelin Medicin AB regarding the rights to the products Coreflow® Soft Stent and the Schelin Catheter®. The agreement states that 2 percent of the invoiced amount for these products must be paid in royalties to Schelin Medicin AB, provided that the company reports a profit and that a patent has been granted. The royalties can amount to a maximum of SEK 4 million per year and a maximum of SEK 20 million in total. The agreement shall cease to apply once SEK 20 million has been paid out to Schelin Medicin AB.

Valuation of intangible assets

The reported capitalized expenses for development work are subject to management's impairment test. The most critical assumption, evaluated by management, relates to whether the intangible asset is expected to generate future economic benefits, which at least must correspond to the carrying amount of the intangible asset. Management has determined that the expected future cash flows are sufficient to justify the carrying amount of the intangible asset, which is why no write-down has been made. However, the valuation is based on and dependent on the conditions for continued operation.

Remuneration policy

The guiding principle is that ProstaLund will offer its management and key personnel competitive remuneration based on the market situation, the company's performance and individual performance. The design of the remuneration policy shall ensure that management and key personnel and the shareholders have common goals.

Shares

ProstaLund AB is listed on the Nasdaq First North Growth Market. The company is traded under the ticker name PLUN and the ISIN code SE0002372318. The Certified Adviser is Västra Hamnen Corporate Finance AB.

The number of shares at the end of the period was 76,588,737. and the quota value was SEK 0.1 per share. All shares are of the same type and have the same voting rights.

Through the right issue the number of shares in ProstaLund will increase from current 76 588 737 to 123 038 037 shares and the share capital will increase from SEK 7 658 873,70 to SEK 12 303 803,70.

Upon full exercise of the warrants of series TO 3 issued in connection with the rights issue, the number of shares will increase by an additional 22,976,619, from 122,541,975 to 145,518,594, and the share capital will increase by an additional SEK 2,297,661.90, from SEK 12,254,197.50 to SEK 14,551,859.40. If the rights issue is fully utilised for subscription of new shares in the Company, the number

of shares in the Company will increase by an additional 248,031 shares to a total of 123,286,068 shares, and the share capital will increase by an additional SEK 24,803.10 to SEK 12,328,606.80 (calculated on the number of outstanding shares and the share capital in the Company after the rights Issue and the compensation Issue).

Annual report

The annual report for 2023 was published on April 19, 2024. The annual report is available on the company's website, www.prostalund.se.

Annual General Meeting

The Annual General Meeting 2024 was held on May 30th in Lund.

Financial calendar

- 2024-11-01 Interim report Jul-Sep 2024
- 2025-02-20 Year-end report 2024

Scope of the report

This year-end report covers the period from January 1, 2024 to June 30, 2024. The comparative information in the report refers to the corresponding period in 2023, unless otherwise stated. All information in the report refers to ProstaLund AB (publ). No consolidation of the wholly owned subsidiaries is performed since they are an insignificant part of the operations. For the full year 2023 the subsidiaries accounted for less than 1% of the total sales and profit.

Accounting policies

This report has been prepared in accordance with the Swedish Annual Accounts Act and the Swedish Accounting Standards Board's general advice. Accounting principles and calculation methods applied are in accordance with the accounting principles used in the preparation of the most recent annual report.

Audit

This report has not been subject to review by the company's auditors.

Assurance of the Board of Directors and Managing Director

The Board and the Managing Director assure that the interim report provides a fair overview of the company's operations, position and results, and describes significant risks and uncertainty factors that ProstaLund AB face.

Lund, 19 August 2024

Per Langö
Chairman of the Board

Tomas Eriksson
Board member

Paul de Potocki
Board member

Tom Rönnlund
Board member

Marianne Östlund
Board member

Anders Kristensson
Verkställande direktör

Sharholder information

For questions about this report, please contact:

Anders Kristensson CEO, ProstaLund AB (publ)

- Tel: 0769-42 12 16
- E-post: anders.kristensson@prostalund.com

Publication

This information is information that ProstaLund AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person named above, on August 19, 2024 at 07:30 a.m. CET.

Income Statement in Summary

KSEK	APRIL-JUNE 2024	APRIL-JUNE 2023	JAN-JUNE 2024	JAN-JUNE 2023	JAN-DEC 2023
Operating income					
Net sales	2 816	5 335	6 316	10 853	22 062
Cost of goods sold	-729	-1 733	-1 789	-3 488	-6 472
Gross profit	2 087	3 602	4 527	7 365	15 590
Sales and Marketing expenses	-4 276	-4 309	-7 719	-8 415	-17 855
Administrative expenses	-3 350	-1 608	-6 016	-3 314	-9 316
Research and development costs	-1 616	-1 343	-2 687	-2 437	-5 019
Other operating income	98	-	356	-	669
Capitalized development expenditure	-105	-364	-355	-364	-926
Operating profit/loss	-7 162	-4 022	-11 894	-7 165	-16 857
Profit/loss from financial items					
Interest income and similar profit/loss items	63	-	27	1	14
Interest expenses and similar profit/loss items	-110	-52	-101	-93	-173
Profit/loss after financial items	-7 209	-4 074	-11 968	-7 257	-17 016
Tax expenses	-	-	-	-	-
Profit/loss for the period	-7 209	-4 074	-11 968	-7 257	-17 016

Per share data

	APRIL-JUNE 2024	APRIL-JUNE 2023	JAN-JUNE 2024	JAN-JUNE 2023	JAN-DEC 2023
Earnings per share, SEK (basic and diluted)	-0,09	-0,07	-0,16	-0,12	-0,25
Equity per share, SEK	0,57	0,84	0,66	0,51	0,81
Equity-asset ratio, %	78%	82%	78%	82%	84%
Number of outstanding shares	76 588 737	75 861 146	76 588 737	75 861 146	76 588 737
Average number of outstanding shares	76 588 737	63 415 818	76 588 737	60 304 486	68 446 612

Note: All figures above concerns the parent company ProstaLund AB (publ). For more info look at page 6 under Scope of the report.

Definitions of financial ratios

Earnings per share

Profit/loss for the period divided by average weighted number of shares.

Equity-asset ratio

Equity divided by total assets.

Equity per share

Equity divided by number of shares at the end of the period.

Balance Sheet in Summary

All amounts in SEK thousand	2024-06-30	2023-06-30	2024-03-31	2023-12-31
Assets				
Intangible assets	30 701	25 915	29 374	28 038
Property, plant & equipment	398	445	346	396
Financial assets	464	464	464	464
Inventories	15 292	13 676	15 957	16 955
Trade receivables	1 233	1 517	2 097	2 182
Receivables from group companies	-	-	-	-
Other receivables	4 347	1 879	2 000	2 504
Cash and bank balances	3 380	34 062	6 944	15 019
Total assets	55 815	77 958	57 182	65 558
Equity and liabilities				
Equity	43 321	64 269	50 530	55 289
Interest-bearing liabilities, longterm	733	1 133	833	933
Current interest-bearing liabilities	4 430	400	400	400
Liabilities to group companies	165	-	-	98
Trade payables	5 961	10 440	3 859	6 413
Other liabilities	1 205	1 716	1 560	2 425
Total equity and liabilities	55 815	77 958	57 182	65 558

Summary statement of changes in equity

All amounts in SEK thousand	2024-06-30	2023-06-30	2023-12-31
Opening balance	55 289	41 684	41 684
New share issues	-	32 669	33 942
Cost of new share issues	-	-3 135	-3 321
Profit/loss for the period	-11 968	-7 257	-17 016
Closing balance	43 321	63 961	55 289

Note: All figures above concerns the parent company ProstaLund AB (publ). For more info look at page 6 under Scope of the report.

Cash Flow Analysis in Summary

All amounts in SEK thousand	APRIL-JUNE 2024	APRIL-JUNE 2023	JAN-JUNE 2024	JAN-JUNE 2023	JAN-DEC 2023
Profit/loss after financial items	-7 209	-4 073	-11 968	-7 257	-17 016
Adjustments for non-cash items	26	61	104	121	265
Tax paid	-	-	-	-	-
Cash flow from operating activities before changes in working capita	-7 183	-4 012	-11 864	-7 136	-16 751
Changes in working capital	-1 094	-3 521	-836	1 130	-6 967
Cash flow from operating activities	-6 089	-491	-12 700	-6 006	-23 718
Capitalization of development expenditure	-1 354	-712	-2 718	-1 027	-3 200
Acquisition/disposal of property, plant & equipment	-51	-101	-51	-101	-146
Acquisition/disposal of financial fixed assets	-	-	-	-	-
Cash flow from investing activities	-1 405	-813	-2 769	-1 128	-3 346
New share issue	-	32 669	-	32 669	33 942
Transaction costs attributable to new share issue	-	-3 135	-	-3 135	-3 321
Change in bank overdraft facilities	4 030	1 000	4 030	1 000	1 000
Change in bank overdraft facilities	-100	-1 100	-200	-1 200	-1 400
Cash flow from financing activities	3 930	29 434	3 830	29 334	30 221
Total cash flow for the period	-3 564	28 130	-11 639	22 200	3 157
Cash and cash equivalents at start of period	6 944	5 932	15 019	11 862	11 862
Cash and cash equivalents at end of period	3 380	34 062	3 380	34 062	15 019

Note: All figures above concerns the parent company ProstaLund AB (publ). For more info look at page 6 under Scope of the report.

Business overview

The Company in brief

ProstaLund is a Swedish company with headquarters in Lund. The company's registration number is 556745-3245. ProstaLund is a Swedish public limited company that was registered at the Swedish Companies Registration Office on December 4, 2007. The Board has its registered head office in the municipality of Lund and operations are based in Sweden. The company's office address is Scheelevägen 19 in Lund with telephone number +46 46-12 09 08. The company's website is www.prostalund.se. The company is a reconciliation company and its share register is kept by Euroclear Sweden AB. In addition to ProstaLund, which is the parent company, the group includes the wholly owned subsidiaries Nordisk Medicin & Teknik AB ("NMT") and the American subsidiary CoreTherm® Medical Inc. ("CMI").

Introduction to the Company's operations

The company develops, markets and sells products in urology. The majority of the sales are made through recurring sales of disposable catheters and other accessories that are used together with the Company's platform in the treatment of BPH/BPE.

The company has a treatment concept (CoreTherm® Concept) for individually adapted heat treatment for benign prostate enlargement, also called BPE or BPH, which mainly affects men over 50 years of age.

In recent years, the company has developed a new platform, CoreTherm® Eagle, which received market approval through a CE marking based on the EU's medical technology regulations (MDR) in February 2023.

The platform now has, among other things, a built-in computer, temperature reading in real time, storage of patient data and built-in recommendations for treating doctors. The company believes that CoreTherm® Concept constitutes one of the market's best treatments against BPH/

BPE with regards to parameters such as treatment results, possibility to treat regardless of prostate size, retreatment frequency, treatment time, fewer complications compared to surgical intervention, learning time for doctors and cost of a treatment. CoreTherm® Concept consists of several patented and unique inventions where the machine's treatment control is based on 25 years of research and clinical experience.

At the same time, the Company has two independent products, Schelin Catheter® and CoreFlow® Soft Stent, which were launched in Europe in September 2022 with very good results. These products have shown strong growth for the full year 2023 compared to the previous year and their share of the Company's total sales now corresponds to 15%. It is the Company's opinion that the products are unique because there are no similar products on the market as a result of the Company holding patents for both products in the markets in which the Company operates.

The company's product range is CoreTherm® Concept, which consists of anesthetic catheters (Schelin Catheter®), treatment catheters (CoreTherm® Catheter) and aftercare catheters (CoreFlow® Soft Stent).

Schelin Catheter® and CoreFlow® Soft Stent are also sold for use in other treatment methods outside of the CoreTherm® Concept. The company also sells the urine flow meter Oruflow.



CoreTherm® Catheter



CoreFlow® Soft Stent

CoreTherm® Concept – Treatment concept

CoreTherm® Concept is a patented and individually adapted treatment concept of BPH/BPE through heat.

CoreTherm® Concept is used today primarily in public hospitals and private clinics in the Nordics region. In 2023, the company had approximately 20 percent market share of the treatments performed in Sweden. The treatment is evidence-based and has the same end result as surgery¹. The concept has a number of advantages:

- The size of the prostate does not limit the method
- The treatment is performed under local anesthesia, as compared with full anesthesia during surgery
- Maximum treatment time is 15 minutes

During a CoreTherm® Concept treatment, the temperature is measured in real time. The treatment effect can thus be calculated continuously and with the help of the temperature monitoring, the responsible doctor or nurse can control the treatment. The treatment takes a maximum of 15 minutes and the entire visit to the reception takes around 1 hour in total.

Schelin Catheter® - Injection tool

Schelin Catheter® is a patented and unique product that has a built-in needle in the catheter intended for intra-prostatic and periprostatic injection of drugs directly into the prostate. With the Schelin Catheter®, anesthetics and adrenaline are administered to manage pain and prostatic blood flow during a CoreTherm® Concept treatment of BPH/BPE, and the catheter thus plays a central role in the development of the treatment concept.

The product can also be used in other contexts, for example before local anesthesia and other treatment procedures for ailments of the prostate, where drugs need to be administered into the prostate sterily. Since the launch, September 2022, the Company has had greatly increased demand for the product in Europe.

CoreFlow® Soft Stent – Aftercare product

CoreFlow® Soft Stent is a patented and unique product. The product is a hybrid between a catheter and a stent and has many uses. The product can be used as a disposable product after the BPH/BPE treatment regardless of the treatment method. The product can also be used as a diagnostic tool and simulate what the results of treatment might be prior to undergoing an invasive measure against obstruction, microwave therapy (TUMT) or transurethral resection (TURP). The product is also an alternative to an indwelling catheter (CAD) in case of urinary retention, which enables self-drainage and reduces the risk of urinary tract infection. CoreFlow® Soft Stent can partially replace urodynamic examinations, as well as be used where such examinations are not possible.

This product is also used outside of the CoreTherm® Concept treatment and is sold as a stand-alone product in Europe together with the Schelin Catheter® (see above).



Schelin Catheter®



CoreTherm® Eagle

1. Mattiasson A., Wagrell L., Schelin S., et al: Five-year follow up of feed-back microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 69, 91-97, 2007



ProstaLund is a Swedish medtech company, a leader in the development of innovative urology products and treatments. ProstaLund has patented CoreTherm®, customised thermal treatment of Benign Prostatic Enlargement (BPE).

ProstaLund AB
Scheelevägen 19
SE-223 63 Lund

info@prostalund.com

Tel: +46 46-12 09 08

www.prostalund.se

